Navigation Links
Al Novak Elected Chairman of the Board of OrbusNeich Medical
Date:12/9/2009

HONG KONG, Dec. 9 /PRNewswire/ -- OrbusNeich today announced that Al Novak has been elected chairman of the board.

Novak, 61 years old, will continue to serve as president and chief executive officer of OrbusNeich, the role that he has held since 2008. He brings over 27 years of leadership experience in the medical technology industry to the position having served as chief executive officer of Novoste Corporation and Biosense, Inc. and in marketing and financial positions with Cordis Corporation including vice president and chief financial officer. Mr. Novak was a founder of Syntheon LLC and also serves on the board of directors of Cyberonics Inc., a NASDAQ listed company.

"Al Novak's election as chairman comes at an important time in the growth of OrbusNeich as a global medical device company," said Teddy Chien, the company's former chairman who will remain a board member and chairman emeritus. "We are confident that Al will continue to lead this company toward additional expansion and the development of competitive, innovative technology that meets the needs of interventional cardiologists."

Novak added: "We are grateful to Teddy for his commitment to OrbusNeich and for his many contributions to interventional cardiology. His vision of building a global medical device company that capitalizes on distinct geographical opportunities based on local market expertise and relationships is one that will continue to drive our business."

Teddy Chien has had a distinguished career working with the medical community over the past 50 years in various capacities at pharmaceutical and medical device companies. In 1979, Chien founded Neich Medical as the exclusive representative for Cordis Corporation in Asia, which was subsequently sold to Johnson and Johnson when it acquired Cordis in 1996. Neich Medical was relaunched in 1999 with the vision to design and build its own cardiology products. Neich Medical and Orbus Medical Technologies merged in 2005 to form OrbusNeich Medical.

Mr. Chien has made many contributions to the cardiology community. He is most proud of founding, in conjunction with leading cardiologists in the Asia/Pacific region, The Chien Foundation. The Foundation was established to provide cardiology fellowships in developing countries in Asia and to foster goodwill and training opportunities among interventional cardiologists within the region. The Foundation also supports keynote lectures and Young Investigator Awards at major conferences within Asia.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Bio-engineered R stent, as well as stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent, Scoreflex(TM), SafeCut(TM), Sapphire(TM), Sapphire NC, Avita(TM), Avita HP and Lumina(TM). OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo, Japan; and Shenzhen, China. OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

SOURCE OrbusNeich


'/>"/>
SOURCE OrbusNeich
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Daniel K. Spiegelman Elected to Board of Directors of Omeros
2. Omnicell Selected by Nations Third Largest Public Healthcare System for Medication Management Systems
3. Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries
4. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
5. Zyomyx Point-of-Care CD4 Test Selected by CD4 Initiative to Help Treat HIV/AIDS Patients in Developing Countries
6. Varian Medical Systems Selected to Supply Major Project to Bring Advanced Radiotherapy Treatments to North of Portugal
7. Sanovia Selected to Deliver PA-Logic(TM) Pharmaceutical Prior Authorization Platform to HealthSpring
8. A Unique Endoluminal Approach for the Treatment of Morbid Obesity Selected for Presentation at the 2009 American College of Surgeons Clinical Congress
9. Fresenius Medical Care, N.A. Has Selected VitalRemedyMDs VitalProteinRx(TM) As Its Bar of Choice for Protein Replacement in Dialysis Patients
10. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
11. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
(Date:9/19/2017)... LOUISVILLE, Ky. , Sept. 19, 2017   ZirMed ... and predictive analytics, today announced that it has been ranked ... the Black Book™ Rankings 2017 User Survey. ZirMed ... software solution for large hospitals and medical centers over 200 ... in Black Book,s healthcare technology user survey history. ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 ... performance ratings for global supply chains, has published the first annual edition ... CSR performance of more than 20,400 companies evaluated by EcoVadis, based on ... 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... of $3,296 in property taxes a year. In some states—like New York, New ... , By contrast, many overseas retirement havens have extremely low property-tax rates, which ...
Breaking Medicine News(10 mins):